|
Jan. 23, 2022 |
|
|
Jan. 23, 2022 |
|
|
jRCT1071210120 |
An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial' (W-JHS NHL02-A) |
|
W-JHS NHL02-A study (W-JHS NHL02-A) |
Akashi Koichi |
||
Kyushu University Graduate School of Medical Science |
||
3-1-1 Maidashi, Higashi-ku, Fukuoka-city, Fukuoka 812-8582, Japan |
||
+81-92-642-5230 |
||
akashi@med.kyushu-u.ac.jp |
||
Koji Kato |
||
Kyushu University Hospital |
||
3-1-1 Maidashi, Higashi-ku, Fukuoka-city, Fukuoka 812-8582, Japan |
||
+81-92-642-5230 |
||
kato.koji.429@m.kyushu-u.ac.jp |
Not Recruiting |
July. 01, 2018 |
||
| April. 25, 2019 | ||
| 20 | ||
Observational |
||
1) Patients enrolled in W-JHS NHL02 study (jRCT2071210101) |
||
Nothing particular |
||
| 20age old over | ||
| No limit | ||
Both |
||
Peripheral T-cell lymphoma (including extranodal NK/T-cell lymphoma) |
||
Gene and protein expression, gene mutation, lymphocyte subset analysis, serum cytokine and chemokine, HLA gene, single cell analysis |
||
Nothing |
||
| Kyushu University Hospital |
| Ono Pharmaceutical Co., Ltd. | |
| Not applicable |
| NPO Clinical Research Network Fukuoka Ethics Committee | |
| 3-1-1 Maidashi, Higashi-ku, Fukuoka-city, Fukuoka 812-8582, Japan, Fukuoka | |
+81-92-643-7171 |
|
| mail@crnfukuoka.jp | |
| Approval | |
Sept. 20, 2018 |
No |
| UMIN000034502 | |
| University hospital Medical Information Network (UMIN) |
none |